Live Breaking News & Updates on Germany Heidelberg Pharmaceuticals

Stay updated with breaking news from Germany heidelberg pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , South Africa , Coted Ivoire , Macau General , Hong Kong , Ivory Coast , Reza Fathi , Adi Frish , Redhill Biopharma , Jeffrey Kugelman , National Institutes Of Health , Us Department Of Defense , Us Army Medical Research , Gilead Sciences Inc , Product Development Pipeline , Prnewswire Redhill Biopharma Ltd , Company Expanded Access Program , Us Army , Germany Heidelberg Pharmaceuticals , Us Army Ebola , Nuclear Countermeasures Program , Molecular Biology Division , Redhill Biopharma Ltd , Corporate Business Development , Exchange Commission , Centers For Disease ,

RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K -December 20, 2023 at 08:58 am EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K
. ....

Macau General , United States , Coted Ivoire , Hong Kong , United Kingdom , Tel Aviv , South Africa , Ivory Coast , Dror Ben Asher , Jeffrey Kugelman , Reza Fathi , Redhill Biopharma , Adi Frish , Us Department Of Defense , Gilead Sciences Inc , Us Army Ebola , Commission File No , Germany Heidelberg Pharmaceuticals , Exchange Commission On , Centers For Disease , Company Annual Report On Form , Product Development Pipeline , Corporate Business Development , Company Expanded Access Program , National Institutes Of Health , National Institute Of Allergy ,

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study. ....

United Kingdom , South Africa , United States , Macau General , Hong Kong , Coted Ivoire , Ivory Coast , Redhill Biopharma , Adi Frish , Redhill Biopharma Ltd , Nuclear Countermeasures Program , Department Of Defense , Germany Heidelberg Pharmaceuticals , Department Of The Navy , Consortium For Enhanced Sepsis Outcomes , Exchange Commission , Corporate Business Development , National Institutes Of Health Radiation , Company Expanded Access Program , Department Of The Army , Company Annual Report On Form , Gilead Raday , Chief Operating Officer , Military Medicine , Acute Radiation Syndrome , National Institutes ,

RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde ....

United Kingdom , Macau General , United States , Hong Kong , Adi Frish , Redhill Biopharma , Germany Heidelberg Pharmaceuticals , Program Executive Office For Chemical , Exchange Commission , Company Expanded Access Program , Department Of The Navy , Corporate Business Development , National Institutes Of Health Radiation , Department Of The Army , Redhill Biopharma Ltd , Nuclear Defense , Nuclear Countermeasures Program For Acute Radiation Syndrome , Consortium For Enhanced Sepsis Outcomes , Company Annual Report On Form , Department Of Defense , Military Medicine , Gilead Raday , Chief Operating Officer , National Institutes , Health Radiation , Nuclear Countermeasures Program ,

RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5

RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Macau General , Hong Kong , Colleenb Jonsson , Harriet Van Vleet , Redhill Biopharma , Reza Fathi , Adi Frish , Us National Institute Of Health , Institute For The Study Of Host , Redhill Biopharma Ltd , Exchange Commission , Company Annual Report On Form , University Of Tennesseehealth Sciences Center , Company Expanded Access Program , Forum Infectious Diseases , University Of Tennessee Health Sciences Center , Corporate Business Development , Development Of Opaganib , Regional Biocontainment Laboratory , Germany Heidelberg Pharmaceuticals , Prnewswire Redhill Biopharma Ltd , Tennesseehealth Sciences , Hill Biopharma , Harriet Van Vleet Professor , Host Pathogen Systems , Tennessee Health Sciences Center ,